PMID- 14581419
OWN - NLM
STAT- MEDLINE
DCOM- 20031120
LR  - 20220409
IS  - 0732-183X (Print)
IS  - 0732-183X (Linking)
VI  - 21
IP  - 21
DP  - 2003 Nov 1
TI  - Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant 
      hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the 
      prostate: the Radiation Therapy Oncology Group Protocol 92-02.
PG  - 3972-8
AB  - PURPOSE: Radiation Therapy Oncology Group (RTOG) Protocol 92-02 was a randomized 
      trial testing long-term (LT) adjuvant androgen deprivation (AD) after initial AD 
      with external-beam radiotherapy (RT) in patients with locally advanced prostate 
      cancer (PC; T2c-4) and with prostate-specific antigen level less than 150 ng/mL. 
      PATIENTS AND METHODS: Patients received a total of 4 months of goserelin and 
      flutamide, 2 months before and 2 months during RT. A radiation dose of 65 to 70 
      Gy was given to the prostate and a dose of 44 to 50 Gy to the pelvic lymph nodes. 
      Patients were randomly assigned to receive no additional therapy (short-term 
      [ST]AD-RT) or 24 months of goserelin (LTAD-RT); 1,554 patients were entered onto 
      the study. RESULTS: The LTAD-RT arm showed significant improvement in all 
      efficacy end points except overall survival (OS; 80.0% v 78.5% at 5 years, P 
      =.73), compared with the STAD-RT arm. In a subset of patients not part of the 
      original study design, with tumors assigned Gleason scores of 8 to 10 by the 
      contributing institutions, the LTAD-RT arm had significantly better OS (81.0% v 
      70.7%, P =.044). There was a small but significant increase in the frequency of 
      late radiation grades 3, 4, and 5 gastrointestinal toxicity ascribed to the 
      LTAD-RT arm (2.6% v 1.2% at 5 years, P =.037), the cause of which is not clear. 
      CONCLUSION: The RTOG 92-02 trial supports the addition of LT adjuvant AD to STAD 
      with RT for T2c-4 PC. In the exploratory subset analysis of patients with Gleason 
      scores 8 to 10, LT adjuvant AD resulted in a survival advantage.
FAU - Hanks, Gerald E
AU  - Hanks GE
AD  - Fox Chase Cancer Center and Radiation Therapy Oncology Group, Phialdelphia, PA 
      19107, USA.
FAU - Pajak, Thomas F
AU  - Pajak TF
FAU - Porter, Arthur
AU  - Porter A
FAU - Grignon, David
AU  - Grignon D
FAU - Brereton, Harmart
AU  - Brereton H
FAU - Venkatesan, Varagur
AU  - Venkatesan V
FAU - Horwitz, Eric M
AU  - Horwitz EM
FAU - Lawton, Colleen
AU  - Lawton C
FAU - Rosenthal, Seth A
AU  - Rosenthal SA
FAU - Sandler, Howard M
AU  - Sandler HM
FAU - Shipley, William U
AU  - Shipley WU
CN  - Radiation Therapy Oncology Group
LA  - eng
GR  - CA-21661/CA/NCI NIH HHS/United States
GR  - CA-32115/CA/NCI NIH HHS/United States
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Clin Oncol
JT  - Journal of clinical oncology : official journal of the American Society of 
      Clinical Oncology
JID - 8309333
RN  - 0 (Androgen Antagonists)
RN  - 0 (Antineoplastic Agents, Hormonal)
RN  - 0F65R8P09N (Goserelin)
SB  - IM
EIN - J Clin Oncol. 2004 Jan 15;22(2):386
MH  - Adenocarcinoma/*drug therapy/mortality/pathology/*radiotherapy
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Androgen Antagonists/*administration & dosage
MH  - Antineoplastic Agents, Hormonal/*administration & dosage
MH  - Chemotherapy, Adjuvant
MH  - Combined Modality Therapy
MH  - Disease-Free Survival
MH  - Drug Administration Schedule
MH  - Goserelin/*administration & dosage
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Prognosis
MH  - Prostatic Neoplasms/*drug therapy/mortality/pathology/*radiotherapy
MH  - Radiation Dosage
MH  - Survival Analysis
MH  - Treatment Outcome
EDAT- 2003/10/29 05:00
MHDA- 2003/12/03 05:00
CRDT- 2003/10/29 05:00
PHST- 2003/10/29 05:00 [pubmed]
PHST- 2003/12/03 05:00 [medline]
PHST- 2003/10/29 05:00 [entrez]
AID - JCO.2003.11.023 [pii]
AID - 10.1200/JCO.2003.11.023 [doi]
PST - ppublish
SO  - J Clin Oncol. 2003 Nov 1;21(21):3972-8. doi: 10.1200/JCO.2003.11.023.